Modelling within-host macrophage dynamics in influenza virus infection

Ke Li^a, James M. McCaw^{a,b,c}, Pengxing Cao^a

^a*School of Mathematics and Statistics, The University of Melbourne, Parkville, VIC 3010, Australia*

^b*Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital and The University of Melbourne, Parkville, VIC 3010, Australia*

^c*Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC 3010, Australia*

Abstract

Human respiratory disease associated with influenza virus infection is of significant public health concern. Macrophages, as part of the front line of host innate cellular defence, have been shown to play an important role in controlling viral replication. However, fatal outcomes of infection, as evidenced in patients infected with highly pathogenic viral strains, are often associated with prompt activation and excessive accumulation of macrophages. Activated macrophages can produce a large amount of pro-inflammatory cytokines, which leads to severe symptoms and at times death. However, the mechanism for rapid activation and excessive accumulation of macrophages during infection remains unclear. It has been suggested that the phenomena may arise from complex interactions between macrophages and influenza virus. In this work, we develop a novel mathematical model to study the relationship between the level of macrophage activation and the level of viral shedding in influenza virus infection. Our model combines a dynamic model of viral infection, a dynamic model of macrophages and the essential interactions between the virus and macrophages. Our model predicts that the level of macrophage activation can be negatively correlated with the level of viral shedding when viral infectivity is sufficiently high. We further identify that temporary depletion of resting macrophages in response to viral infection is a major driver in our model for the negative relationship between macrophage activation and viral shedding, providing new insight into the mechanisms that regulate macrophage activation. Our model serves as a framework to study the complex dynamics of virus-macrophage interactions and provides a

mechanistic explanation for existing experimental observations, contributing to an enhanced understanding of the role of macrophages in influenza viral infection.

11 *Keywords:* Mathematical modelling, Influenza virus, Macrophage

12 1. Introduction

13 Influenza is a contagious respiratory disease caused by influenza viruses.
 14 Infection with influenza A virus (IAV) in particular remains as a major public
 15 health concern, resulting in heavy morbidity worldwide every year [1].
 16 Epithelial cells, which line the upper respiratory tract (URT) of the host, are
 17 the primary target cells for influenza virus infection [2, 3], and virus-induced
 18 cell damage is often thought to be the main cause for clinical symptoms and
 19 a determinant of virulence [4, 5, 6, 7]. During an infection, host immunity
 20 plays an important role for viral resolution and host recovery. The innate
 21 (or nonspecific) immune system is the first and primary defence mechanism
 22 that is triggered upon detection of an IAV infection. Macrophages, as part
 23 of the innate immune cellular response, are activated at the early stages of
 24 infection [8, 9, 10]. They perform two important antiviral functions. One
 25 is the uptake of viruses mediated by the interaction of pattern-recognition
 26 receptors (PRRs), such as the Toll-like receptors (TLRs), in macrophages
 27 with pathogen-associated molecular patterns (PAMPs) on the virus, and the
 28 phagocytosis of apoptotic virus-infected cells [11, 12, 13, 14]. The other is the
 29 secretion of cytokines and chemokines, such as tumor necrosis factor-alpha
 30 (TNF- α), interleukins-6 (IL-6) and interferons (IFNs), by which macrophages
 31 can modulate inflammatory responses and help trigger an adaptive immune
 32 response, attracting effector cells to the site of infection. [15, 16, 17].

33 Macrophages are highly heterogeneous in the host and can alter their
 34 phenotypes and functions rapidly in response to local stimuli [18, 19, 20]. In
 35 response to a viral infection, resting macrophages are activated and give rise
 36 to two major types of macrophages, denoted M_1 and M_2 in terms of function-
 37 ality [21]. M_1 macrophages have a stronger capability to engulf free virions,
 38 present antigens to other immune cells and produce pro-inflammatory cy-
 39 tokines which contribute to both host inflammatory responses and pathogen
 40 clearance [18]. In contrast, M_2 macrophages primarily secrete anti-inflammatory
 41 cytokines to mitigate inflammation and maintain host homeostasis [22]. While
 42 viral infection-induced cell death and tissue damage are thought to be the

primary contributors to host morbidity, further evidence has shown that over-expression of pro-inflammatory cytokines and chemokines mediated by activated macrophages may also be a cause for lung pathology [23, 24, 25, 26, 24, 27]. Unregulated pulmonary infiltration of macrophages is often the hallmark of severe influenza virus infection [28, 29, 30], as reviewed in [31]. For instance, mice infected with highly pathogenic (HP) influenza virus experienced rapid infiltration of macrophages and excessive accumulation of macrophages during infection, showing fatal infection results with a high level of viral shedding. These outcomes were not observed in mice infected with low virulent strains [32]. The observations suggest a positive correlation between the level of macrophage activation and the level of viral shedding. However, since the interactions between different types of macrophages and between macrophages and influenza virus involve both positive and negative feedback mechanisms (see review [33]), it is not clear how this relationship can arise from a dynamical system of virus-macrophage interactions and under what condition(s) such a relationship may no longer be valid. In this paper, we study these interactions using a mathematical model.

Mathematical models have been used to explore macrophage dynamics in different pathological environments, e.g., in bacterial infection [34, 35] (particularly in tuberculosis infection (TB) [36]) and for tumors [37]. Some models in the literature have been used to specifically investigate the interactions between M_1 and M_2 macrophages [38, 39]. Models have also been used to study within-host influenza virus dynamics, many of which have been designed to explore how the viral load kinetics is modulated by different immunological factors (see reviews [40, 41, 42]). However, in the literature, there are no influenza virus infection models which explicitly include both M_1 and M_2 macrophage dynamics as part of the innate immune responses.

In this paper, we develop a novel mathematical model, which combines a dynamic model of influenza virus infection, a dynamic model of macrophages and the essential interactions between virus and macrophages. We use the model to explore the dynamics of macrophages in response to influenza viral infection and investigate how the level of macrophage activation is influenced by the viral infectivity (which is a critical parameter determining the level of viral shedding). Our aim is to explore in detail possible explanation(s) for the mechanism determining the aforementioned relationship between viral shedding and macrophage activation. Finally we discuss our findings and the biological implications of our model results.

2. Methods

We first introduce a dynamic model of macrophages, which incorporates three distinct populations and the conversion processes between them, in the absence of viral infection. We then incorporate the macrophage model into an influenza viral infection model which captures the minimal essential processes to describe IAV kinetics, including viral multiplication via the infection of epithelial cells and viral resolution by antibodies.

2.1. A dynamical model of macrophages

The model of macrophage dynamics contains three macrophage populations: M_1 (so called “classically activated” macrophages), M_2 (so called “alternatively activated” macrophages) [21] and resting macrophages M which have low efficiency to present antigen and produce cytokines. Resting macrophages can convert into either M_1 or M_2 macrophages in response to different stimuli [21, 36]. A diagram representing the model is shown in Fig. 1.

Figure 1: **Macrophage dynamics in the absence of viral infection.** The dashed arrow line indicates that the presence of M_1 promotes the conversion process of M to M_2 . The dashed-bar line denotes suppression of the process of M to M_1 due to M_2 . The solid full-arrow line denotes recruitment of M , and solid half-arrow lines denote the conversion processes among macrophages.

In the absence of infection, M macrophages can be converted into M_1 in response to apoptotic cells as well as tissue debris, and M_1 macrophages stimulate the secretion of pro-inflammatory cytokines, e.g. $\text{TNF-}\alpha$ and $\text{IFN-}\gamma$ [43], which subsequently reinforce the activation process in an autocrine or paracrine manner [44]. M macrophages can also be converted into M_2 macrophages stimulating the secretion of anti-inflammatory cytokines, e.g.

interleukin-10 (IL-10), to mitigate the host inflammatory response and maintain homeostasis [19]. The conversion processes are modelled by a set of ordinary differential equations (ODEs):

$$\begin{aligned} \frac{dM}{dt} = & g \left(1 - \frac{M + M_1 + M_2}{M_0} \right) M - \frac{k_1}{1 + s_1 \frac{M_2}{M_0}} M - k_2 \left(1 + s_2 \frac{M_1}{M_0} \right) M \\ & + k_{-2} M_2 + k_{-1} M_1, \end{aligned} \quad (1)$$

$$\frac{dM_1}{dt} = \frac{k_1}{1 + s_1 \frac{M_2}{M_0}} M - k_{-1} M_1 - \delta M_1, \quad (2)$$

$$\frac{dM_2}{dt} = k_2 \left(1 + s_2 \frac{M_1}{M_0} \right) M - k_{-2} M_2 - \delta M_2. \quad (3)$$

Eq. 1 describes the rate of change of resting macrophages M . It is governed by five processes (corresponding to the five terms on the righthand side of Eq. 1). M are produced at a rate $g(1 - (M + M_1 + M_2)/M_0)M$ mimicking a logistic growth model. To phenomenologically capture the established regulatory effects of M_1 and M_2 [23] as reviewed in [21], the rate of conversion from M to M_1 is modelled by a decreasing function of M_2 with a maximum of k_1 (see the second term on the righthand side of Eq. 1) and the rate of conversion from M to M_2 is modelled by an increasing function of M_1 with a minimum of k_2 (see the third term on the righthand side of Eq. 1). The parameters s_1 and s_2 modulate the dependence of the conversion rates on the number of activated macrophages. M_1 and M_2 macrophages return to the resting state M at rate k_{-1} and k_{-2} when stimuli are diminished, respectively [45].

Eq. 2 and Eq. 3 model the dynamics of M_1 and M_2 , respectively. In addition to the terms describing the conversion between M and M_1 (i.e. the first and second terms on the righthand side of Eq. 2) and between M and M_2 (i.e. the first and second terms on the righthand side of Eq. 3), macrophages M_1 and M_2 decay naturally at rate δ .

2.2. A model coupling macrophage dynamics and viral infection dynamics

Upon detection of virus, resting macrophages M are promptly activated and converted into M_1 via Toll-like receptor (TLR)-dependent signalling pathways, and strong inflammatory responses are initiated [14]. A wide range of inflammatory cytokines and chemokines, such as tumor necrosis

factor-alpha (TNF- α), interleukins-6 (IL-6) and interferons (IFNs), are secreted by proinflammatory macrophages M_1 and lead to the recruitment of more immune cells to the site of infection [46]. Activated macrophages have been shown to have a stronger capacity for phagocytosis of apoptotic cells and antigen presentation compared to those in an inactivated state [47].

Macrophages are activated in response to viral infection and are crucial in providing negative feedback to viral reproduction. For example, activated M_1 macrophages uptake free virions and prime various adaptive immune responses [16, 21]. Here we propose a model to capture the essential regulatory processes between macrophages and influenza virus. A diagram representing the model is shown in Fig. 2, and the processes are modelled by a system of ODEs:

$$\frac{dT}{dt} = -\beta TV, \quad (4)$$

$$\frac{dI}{dt} = \beta TV - \delta_I I, \quad (5)$$

$$\frac{dV}{dt} = pI - cV - \kappa M_1 V - \kappa_a AV, \quad (6)$$

$$\begin{aligned} \frac{dM}{dt} = & g \left(1 - \frac{M + M_1 + M_2}{M_0} \right) M - \frac{k_1}{1 + s_1 \frac{M_2}{M_0}} M - k_2 \left(1 + s_2 \frac{M_1}{M_0} \right) M \\ & + k_{-2} M_2 + k_{-1} M_1 - q_1 IM - q_2 VM, \end{aligned} \quad (7)$$

$$\frac{dM_1}{dt} = \frac{k_1}{1 + s_1 \frac{M_2}{M_0}} M - k_{-1} M_1 - \delta M_1 + q_1 IM + q_2 VM, \quad (8)$$

$$\frac{dM_2}{dt} = k_2 \left(1 + s_2 \frac{M_1}{M_0} \right) M - k_{-2} M_2 - \delta M_2, \quad (9)$$

$$\frac{dA}{dt} = \mu M_1 + \rho \left(1 - \frac{A}{A^*} \right) A. \quad (10)$$

Eqs. 4–6, proposed based on the classic target cell-infected cell-virus (TIV) model, describe the essential dynamics of virus turnover through the infection of target cells and the resolution of infection by immune responses. In detail, target cells (T ; i.e. epithelial cells in influenza infection) are infected with virus (V) and become infected cells (I) at a rate βV . Infected cells produce and release viral progenies (at a rate p) which invade target cells leading to further infection. Free virus (V) decays due to three processes:

Figure 2: **Macrophage dynamics in the presence of viral infection.** Resting macrophages (M) replenish their population in the system (blue arrow towards M) and are activated into either pro-inflammatory macrophages M_1 , or anti-inflammatory macrophages M_2 (blue arrows from M to either M_1 or M_2). The activated macrophages return back to M (as indicated by the blue arrows from M_1/M_2 to M). M_1^+ indicates that M_1 increases the rate of conversion from M to M_1 . In a similar way, M_2^- , V^+ and I^+ indicate that the rate of conversion from M to M_1 is suppressed by M_2 but enhanced by virus V and infected cells I . Virus (V) infects epithelial cells (T), which become infected cells (I) (indicated by the red solid arrow with V^+), and infected cells (I) produce virus (large arrow). M_1 internalise free virions (green solid bar line), and stimulate adaptive immunity (black solid full-triangle line) in which antibodies (A) are produced, by which virions are neutralised (black solid bar line).

145 natural decay at a rate c , internalisation by activated macrophages M_1 at a
 146 rate κM_1 and neutralisation by antibodies at a rate $\kappa_a A$. Infected cells (I)
 147 die naturally at a rate δ_I .

148 Eqs. 7–9 are adapted from the macrophage model (Eqs. 1–3) with some
 149 additional terms capturing the effect of infected cells and virus on the con-
 150 versions from M to M_1 and M_2 . For example, the term $q_1 IM$ models the
 151 conversion of resting macrophages M to M_1 due to the presence of various
 152 infected cell-producing cytokines [48, 49]. The term $q_2 VM$ models virus-
 153 induced macrophage activation via TLR-dependent pathways [16].

154 Eq. 10 models the activation and expansion of adaptive immune re-

sponses, in particular the production of antibodies, which are responsible for clearing virus at the late stages of infection, providing long-term protection. In detail, the production of antibodies (A) is phenomenologically modelled by a logistic growth model (i.e. the second term on the righthand side of Eq. 10) with a growth rate ρ and a carrying capacity A^* , coupled with a “trigger” term due to antigen presentation, μM , which assumes that the strength of triggering the adaptive immune response is proportional to the level of activated macrophage M_1 .

2.3. Model parameters

The values of model parameters are given in Table 1. The parameter values and initial conditions for influenza viral dynamics (such as p , δ_I , $T(0)$, $I(0)$ and $V(0)$) are chosen from the study in [50], in which the authors fitted the TIV model to a set of data from humans infected with A/H1N1 virus. The parameter β is estimated and chosen from the literature such that the viral load shows at least a three-fold increase in infection [51]. To the best of our knowledge, the values for the model parameters which govern either the macrophage dynamics (such as M_0 , k_1 , k_{-1} , k_2 and k_{-2}) or the influenza virus-macrophage interactions (such as q_1 and q_2), are not available. Therefore, we choose those parameter values from [52] in which macrophage dynamics are investigated in a tumour environment. We assume macrophages (M_1 and M_2) have comparable impact on each other and set $s_1 = s_2 = 1$. Also, the assumed carrying capacity for antibodies (A^*) during infection is chosen such that virus can be efficiently cleared.

2.4. Numerical simulation methods

The ordinary differential equations are solved using the ode solver *ode15s* in MATLAB R2019b with a relative tolerance of 1×10^{-5} and an absolute tolerance of 1×10^{-10} . The initial values for the target cell T , the infected cell I and the virus V are given in Table 1. The initial values for the macrophage populations M , M_1 and M_2 are given by the virus-free steady state and are obtained by numerically integrating Eqs. 1–3 (using *ode15s* in MATLAB) for a sufficiently long time interval (see Fig. S1), and choosing the values of M , M_1 and M_2 at the final time point. MATLAB code to produce all the figures in this study can be found at <https://github.com/keli5734/Matlab-Code>.

3. Results

3.1. Dynamics of macrophages and viral shedding

The simulated time series of viral load (V) and two populations of activated macrophages (M_1 and M_2) are shown in Fig. 3A (model solutions for other variables are given in Fig. S2 in the *Supplementary Material 1*). The viral load curve shows a three-phase shape—an exponential growth followed by a slow decay (or a plateau) and finally a rapid decay to viral resolution—typical of observed infection data and simulations of *in vivo* influenza infection [50, 51, 53, 54, 55]. In response to viral infection, activated macrophages M_1 undergo a rapid increase followed by a decrease (Fig. 3A red solid line), while M_2 macrophages experience a decline followed by a replenishment (Fig. 3A red dashed line). The different behaviours of M_1 and M_2 are due to competition for the limited resource (i.e. resting macrophage M). There is a dramatic increase in the conversion from M to M_1 induced by the initial exponential viral growth that rapidly consumes M (see Fig. S2) which in turn reduces the conversion from M to M_2 . M_1 and M_2 gradually return to their homeostatic state upon the resolution of infection (after approximately day 12 in Fig. 3A).

To better understand how the viral load is influenced by macrophages, we present the time series of the four terms on the righthand side of Eq. 6 (Fig. 3B). These four time-series represent the four major processes determining the rate change of viral load (dV/dt) in the model and include viral production (pI), natural death (cV), internalisation by M_1 macrophage ($\kappa M_1 V$) and neutralisation by antibodies ($\kappa_a AV$). The macrophage-mediated innate immune response (dash-dotted line) plays a dominant role in controlling viral replication before antibody takes over on approximately day 9 in the model. A qualitatively similar model behaviour was observed in [51] where the innate immune response was assumed to be mediated by interferon.

3.2. Relationship between the level of macrophage activation and the level of viral shedding

Having examined the time-series behaviour of viral shedding and M_1 macrophages, we now examine the relationship between the level of macrophage activation and the level of viral shedding. The level of macrophage activation is assumed to be the cumulative number of M_1 macrophages because of their key role in producing massive pro-inflammatory cytokines in influenza virus

Figure 3: **Model simulation results of viral shedding kinetics and macrophage dynamics in infection using the parameters values in Table 1.** (A) Viral shedding dynamics (Eq. 6; black solid line), pro-inflammatory macrophages M_1 (Eq. 8; red solid line) and anti-inflammatory macrophages M_2 (Eq. 9; red dashed line). (B) The rate of change of the components on the right-hand side of dV/dt (Eq. 6), which are the rates of viral growth pI (solid line), viral natural decay cV (dot line), virus engulfed by M_1 macrophages $\kappa M_1 V$ (dash-dotted line), and virus neutralized by antibodies $\kappa_a AV$ (dashed line).

infection [56], and we quantify the cumulative number by the area under the M_1 time-series curve (AUC_{M1})

$$AUC_{M1} = \int_0^{\tau} M_1(t) dt,$$

where τ is a cut-off day for computation. The level of viral shedding is assumed in the model to be the cumulative viral load, which has been considered as a surrogate for viral infectiousness of influenza infection [57] and an important marker for viral pathogenicity [58, 59]. It is quantified by the area under the viral load time-series curve (AUC_V)

$$AUC_V = \int_0^{\tau} V(t) dt.$$

In this study, we set $\tau = 15$ which is an appropriate value to cover both the duration of viral infection and the duration of macrophage activation as shown in [32].

Fig. 4 shows the relationship between AUC_{M1} and the AUC_V as viral infectivity (model parameter β) varies. We chose to vary the viral infectivity because it is a key parameter determining the ability of virus to cause infection. We see that for intermediate values of β , the AUC_{M1} and the AUC_V are positively correlated (e.g. in Region II; the definition of the regions are provided in the caption of Fig. 4), consistent with experimental observation [32]. However, we also identify in the model a region where the two quantities are negatively correlated for relatively high β (i.e. Region III), which suggests that a highly pathogenic virus strain may cause a compromised activation of M_1 macrophages while maintaining a high level of viral shedding. In addition, for very small β (i.e. in Region I), viral infection cannot be established because the basic viral reproduction number (provided in the caption of Fig. 4) is less than the infection threshold 1.

It is unclear from Fig. 4 why the negative relationship between the AUC_{M1} and the AUC_V in region III arises, so we examine the time series for the viral load and M_1 macrophages. Fig. 5A and 5B show the time series of viral load and different types macrophages for $\beta = 6.08 \times 10^{-5}$ which is the critical value separating regions II and III. Fig. 5C and 5D show similar time series for a β value inside the region III (i.e. $\beta = 10.08 \times 10^{-5}$). Although the viral load curve for the larger β exhibits a shorter duration of infection compared to that for the smaller β (Fig. 5C v.s. Fig. 5A), it also exhibits a higher peak value such that a higher AUC_V is possible. In contrast, the M_1 macrophage curve for the larger β exhibits both a lower peak value and a shorter duration of activation—quickly reaching a peak and declining—compared to that for the smaller β (Fig. 5D v.s. Fig. 5B), which explains the decrease in AUC_{M1} . In the next section, we will explore the mechanism(s) leading to the reduction in AUC_{M1} .

3.3. *Temporary depletion of M is a mechanism driving the decrease of AUC_{M1} in region III*

Since the production of M_1 macrophages is fundamentally driven by the conversion of resting macrophages M in the model (shown in Fig. 1), we hypothesise that the decrease in AUC_{M1} in region III might be attributed to a more severe (albeit temporary) depletion of M , which is partly supported by Fig. 5B and 5D where the level of M is driven lower and earlier for a larger β .

To investigate our hypothesis, we increase the regrowth rate of M (i.e. the model parameter g), which should mitigate the extent of M depletion

Figure 4: **Simulation results of the change of AUC_{M1} (dash-dotted line) and AUC_V (solid line) to the modulation of viral infectivity $\beta \in [8 \times 10^{-6}, 1.2 \times 10^{-4}]$.** We classify the results into three regions. Regions I and II are separated by the viral basic reproduction number which is given by $R_{V,0} = p\beta T(0)/(\delta_I(c + \kappa M_1(0) + \kappa_a A(0)))$. In region I, $R_{V,0} < 1$. At the boundary between regions I and II, $R_{V,0} = 1$. In regions II and III, $R_{V,0} > 1$. The boundary between regions II and III is determined by a change in the correlation between AUC_{M1} and AUC_V . In region II these two areas are positively correlated whereas in region III they are negatively correlated.

270 by increasing both the rate of M replenishment and the initial number of M
 271 macrophages (i.e. the homeostatic state, see Fig. 6A). As seen in Fig. 6B, as g
 272 increases, region III shrinks while both region I and region II expand. Fig. 6C
 273 provides a more detailed view of how the regions shift for two selected values
 274 of g (in particular the expansion of region II at the expense of a shrinking
 275 region III). These results show that mitigating M depletion (by increasing
 276 the regrowth rate g of M macrophages in the model) can turn a decreasing
 277 AUC_{M1} to increasing for a range of β , confirming our hypothesis that a
 278 temporary depletion of M is a mechanism driving the decrease of AUC_{M1} in
 279 region III.

Figure 5: **Model simulation results of macrophage dynamics and viral shedding kinetics with different viral infectivity β in different regions.** First row (A and B): viral shedding kinetics, and the dynamics of M macrophages (solid line), M_1 macrophages (dash-dotted line) and M_2 macrophages (dashed line) in region II ($\beta = 6.08 \times 10^{-5}$). Second row (C and D): viral shedding kinetics and macrophage dynamics in region III ($\beta = 10.08 \times 10^{-5}$).

3.4. Dependence of the AUC_V - AUC_{M_1} relationship on other model parameters

So far we have varied the viral infectivity β , as a means to examine the relationship between the level of viral shedding and the level of M_1 macrophage activation. We now examine whether our results and conclusions are robust to a change in other virus-related parameters. For example, we vary the viral production rate p and produce a series of figures similar to Figs. 4–6 (see Figs. S3–S5 in *Supplementary Material 1*). We find that the results are qualitatively the same as those for varying β , in particular the existence of region

Figure 6: **Model simulation results of macrophages, AUC_{M1} (dashed line) and AUC_V (solid line) as functions of M regrowth rate g .** (A) The dependence of initial values of macrophage populations on the M regrowth rate g . g is varied from 0.02 to 2.5. Note that the numbers of macrophages become saturated for relatively large g . We show mathematically that there always exists a maximum capacity for M as $g \rightarrow \infty$ (see *Supplementary Materials 2* for detail). (B) shows how regions I, II and III change as g increases. (C) The dependence of the AUC_{M1} and the AUC_V on β for two selected values of g (i.e. $g = 0.2$ and $g = 2$). $\beta \in [8 \times 10^{-6}, 1.2 \times 10^{-4}]$.

289 III (see Fig. S3) and the observed reduction in region III when mitigating
 290 depletion of M by increasing the regrowth rate g (see Fig. S5). Varying κ
 291 (the rate of viral engulfment by M_1) yields similar results (see Figs. S6–S8;

note that the effect of decreasing κ is similar to that of increasing β or p because of the antagonistic processes described by the model).

Figure 7: **Model simulation results of AUC_{M1} (dashed line) and AUC_V (solid line) as functions of q_1 and k_1 , respectively.** (A) The dependence of the AUC_{M1} and the AUC_V on the virus-induced macrophage activation rate q_1 . q_1 is varied from 3×10^{-8} to 1×10^{-5} . (B) The change of the AUC_{M1} and the AUC_V to modulation of the proinflammatory macrophage activation rate $k_1 \in [0.02, 1]$. The AUC_{M1} is indicated by dashed line, and the AUC_V is shown in solid line.

Since experimental studies [26, 27, 29, 30] have suggested highly pathogenic influenza virus strains can infect macrophages and modulate the rate of cytokine production, resulting in rapid macrophage infiltration and strong inflammatory response, we further examine the effect of the rate of M_1 activation, either virus-induced (q_1) or virus-independent (k_1), on the AUC_V – AUC_{M1} relationship. Fig. 7A shows that increasing q_1 leads to an increase in AUC_{M1} but a decrease in AUC_V . A similar result is observed for increasing k_1 (Fig. 7B). The negative relationship between AUC_V and AUC_{M1} in response to a change in the rate of M_1 activation in the model may imply that a viral mutation conveying a change in the rate of M_1 activation will result in either compromised viral shedding or compromised macrophage response and therefore cannot solely explain the aforementioned observation that highly pathogenic influenza virus strains can induce both a higher cell infiltration and a higher level of viral shedding than less pathogenic strains.

308 4. Discussion

309 In this work, we have studied the relationship between viral shedding
 310 and macrophage activation during influenza virus infection through numeri-
 311 cal analysis of a mathematical model which integrates viral infection dynam-
 312 ics, macrophage dynamics and the essential interactions between virus and
 313 macrophages. We find based on the model that viruses with a higher ability
 314 to cause infection (e.g. a higher viral infectivity β or a higher production
 315 rate p in the model) will always lead to a higher level of viral shedding (i.e.
 316 a higher AUC_V) but not necessarily a higher level of macrophage activation
 317 (i.e. a higher AUC_{M1}). For an intermediate range of viral infectivity, the
 318 level of viral shedding and the level of macrophage activation are positively
 319 correlated (shown in Fig. 4; region II), which has been observed in avian IAV
 320 infection [32, 60, 61, 62]. But when the viral infectivity becomes sufficiently
 321 high, the level of macrophage activation declines, leading to an unexpected
 322 negative correlation with the level of viral shedding (shown in Fig. 4; region
 323 III), which is then shown to be caused by a temporary depletion of resting
 324 macrophages M . Our findings not only suggest that a higher viral shedding
 325 may not be accompanied by a higher macrophage response but also high-
 326 light the importance of the pool size of resting macrophages in modulating
 327 the pro-inflammatory response.

328 To the best of our knowledge, our model is the first work to incorporate
 329 the dynamics of heterogeneous macrophage populations into a model of in-
 330 fluenza viral dynamics. Although no macrophage data in the literature can
 331 be used to directly test our model results, there is some indirect evidence from
 332 cytokine data to support our findings. For example, activated macrophages
 333 M_1 can secrete a large amount of cytokines such as interleukin 6 (IL-6) and
 334 tumor necrosis factor (TNF) [21, 63], and evidence from experimental stud-
 335 ies [12, 64, 65] has shown that the level of those pro-inflammatory cytokines
 336 normally rises in the early days of influenza infection and then gradually
 337 decreases afterwards—a kinetic behaviour consistent with the kinetics of M_1
 338 macrophages predicted by our model. Furthermore, alternatively activated
 339 macrophages M_2 are responsible for producing anti-inflammatory cytokines,
 340 such as IL-4 and IL-10, and the time series data of IL-4 from [66] (in which
 341 mice are experimentally inoculated influenza A/PR/8/34 H1N1 virus) show
 342 qualitatively similar kinetics to that of the M_2 macrophages produced by
 343 our model (i.e. an initial decrease followed by a recovery back to baseline, as
 344 shown in Fig. 3A).

Understanding the cause of symptoms due to IAV infection is an important but challenging task. Because the mechanism causing various symptoms remains unclear, we do not have the capacity to accurately model symptom dynamics. However, we can take a heuristic approach to predict the kinetics of symptoms using our model. For example, given that macrophage-mediated inflammatory response contributes to the formation of illness [24, 64, 65], then if we assume a positive correlation between symptom dynamics and the number of M_1 macrophages, our model predicts a delayed presence, peak and resolution of symptoms compared to viral shedding dynamics (Fig. 3A). This prediction is qualitatively consistent with a previous finding that viral shedding preceded the occurrence of symptoms by approximately one day and finished earlier than the symptom resolution [67]. Although there are assumptions to be validated by further experiments, such as the positive correlation between the formation of symptoms and the dynamics of M_1 macrophages, our model provides promising directions to probe the mechanism of symptom formation and establish the relationship between symptoms and immune response dynamics.

Further, macrophages have been shown to have pathological effects in mice infected with highly pathogenic influenza virus [68, 69]. Our model results provide new insight into the possible mechanisms for regulation of macrophage activation, suggesting that the pathological effects can be minimized by influencing the replenishment rate and reducing the available number of resting macrophages (e.g., region III Fig. 4). This may decrease macrophage accumulation and restrict the strength of inflammatory responses. For example, a study in [70] has shown that lethality of IAV infection to mice could be ameliorated when interferon-I (IFN-I) signalling is blocked. The similar knockout can be applied to macrophages and modulate the activation process of macrophages.

Our model can be extended to study other biological processes which are highly dependent upon macrophage dynamics in influenza infection. For instance, macrophages have been shown to have an important role in effective activation of adaptive immunity [12, 68], and quantifying the impact of macrophages upon adaptive immune responses in influenza infection will be a promising direction for further study. Also, biological activities of cell surface mucin (cs-mucin) glycoproteins, MUC1 particularly, have been shown to have an important role in reducing the severity of influenza infection, as reviewed in [71]. MUC1 provides two-fold protection to the host—a physical barrier to prevent virus from infecting healthy cells and more importantly

a regulator of host inflammatory responses via inhibition of signalling pathways on macrophages [72]. Our model has the capacity to model the two protective roles of MUC1. For instance, we could model the physical effect of MUC1 against influenza infection by reducing the viral infectivity β or model the inhibitory effect of MUC1 on inflammatory response by reducing the activation rate of M_1 macrophages. With the data available from [72], we may be able to quantitatively study the effect of MUC1 on reduction of infection severity and inflammatory responses in influenza infection. Another potential application of our model is to predict the effect of novel antiviral treatments, such as Pam2Cys, a novel immunomodulator shown to be able to enhance protection against influenza in mice by stimulating innate immunity and recruiting macrophages to the site of infection [73, 74]. These applications are beyond the scope of this paper and are left for future work.

Author contributions

Ke Li: Conceptualization, Methodology, Software, Formal analysis, Writing-Original Draft. **James M. McCaw** Methodology, Formal analysis, Writing-Review and Editing, Supervision. **Pengxing Cao:** Methodology, Formal analysis, Writing-Review and Editing, Supervision

Acknowledgements

Ke Li is supported by a Melbourne Research Scholarship. This work was supported by an Australian Research Council (ARC) Discovery Project (DP170103076) and a National Health and Medical Research Council (NHMRC) funded Centre for Research Excellence in Infectious Diseases Modelling to Inform Public Health Policy (1078068).

Declarations of interest

None.

Par.	Description	Value	Unit	Reference
p	Viral production rate	7.1×10^{-2}	$[u_V][u_T]^{-1}d^{-1}$	[50]
c	Viral natural death rate	20	d^{-1}	[51]
s_1	Effectiveness of M_2 attenuates $M \rightarrow M_1$	1	-	-
s_2	Effectiveness of M_1 promotes $M \rightarrow M_2$	1	-	-
δ_I	Natural death rate of infected cells	3.6	d^{-1}	[50]
δ	Decay rate of M_1 and M_2	0.02	d^{-1}	[52]
κ	Rate of virus internalisation by M_1	7.7×10^{-4}	$[u_{M_1}]^{-1}d^{-1}$	[34]
κ_a	Neutralisation rate of virus by antibody	0.2	$[u_A]^{-1}d^{-1}$	[51]
μ	Rate of macrophage-induced activation of adaptive immunity	10^{-6}	d^{-1}	-
ρ	logistic growth rate of antibody response	1	d^{-1}	[53]
β	Viral infectivity	3.8×10^{-5}	$[u_V]^{-1}d^{-1}$	-
g	Regrowth rate of M	0.2	d^{-1}	-
M_0	Carrying capacity of macrophage regrowth	10^6	$[u_M]$	[34, 37]
k_1	Conversion rate of $M \rightarrow M_1$	0.5	d^{-1}	[52]
k_{-1}	Conversion rate of $M_1 \rightarrow M$	0.33	d^{-1}	[52]
k_2	Conversion rate of $M \rightarrow M_2$	0.5	d^{-1}	[52]
k_{-2}	Conversion rate of $M_2 \rightarrow M$	0.33	d^{-1}	[52]
q_1	Rate of infected cell-induced conversion from M to M_1	1×10^{-6}	$[u_I]^{-1}d^{-1}$	[34]
q_2	Rate of virus-induced conversion from M to M_1	1×10^{-6}	$[u_V]^{-1}d^{-1}$	[34]
A^*	Assumed carrying capacity of antibody upon an infection	10^5	$[u_A]$	-
$T(0)$	Initial value of uninfected epithelial cells in the upper respiratory tract	4×10^8	$[u_T]$	[50]
$I(0)$	Initial value of infected cells	0	$[u_I]$	[50]
$V(0)$	Initial value of viral load	3.3×10^{-1}	$[u_V]$	[50]

Table 1: **Parameter values used for numerical simulation.** $[\cdot]$ denotes the unit for each variable, e.g., the unit of T is denoted as $[u_T]$. d^{-1} denotes per day.

References

- [1] J. K. Taubenberger, D. M. Morens, The pathology of influenza virus infections, *Annu. Rev. Pathmechdis. Mech. Dis.* 3 (2008) 499–522.
- [2] A. Ibricevic, A. Pekosz, M. J. Walter, C. Newby, J. T. Battaile, E. G. Brown, M. J. Holtzman, S. L. Brody, Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells, *Journal of virology* 80 (15) (2006) 7469–7480.
- [3] D. G. Rosen, A. E. Lopez, M. L. Anzalone, D. A. Wolf, S. M. Derrick, L. F. Florez, M. L. Gonsoulin, M. O. Hines, R. A. Mitchell, D. R. Phatak, et al., Postmortem findings in eight cases of influenza A/H1N1, *Modern Pathology* 23 (11) (2010) 1449–1457.
- [4] C. J. Sanders, P. C. Doherty, P. G. Thomas, Respiratory epithelial cells in innate immunity to influenza virus infection, *Cell and tissue research* 343 (1) (2011) 13–21.
- [5] C. Sweet, H. Smith, Pathogenicity of influenza virus., *Microbiological reviews* 44 (2) (1980) 303.
- [6] T. Ronni, T. Sareneva, J. Pirhonen, I. Julkunen, Activation of IFN- α , IFN- γ , MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells., *The Journal of Immunology* 154 (6) (1995) 2764–2774.
- [7] D. Fujikura, T. Miyazaki, Programmed cell death in the pathogenesis of influenza, *International journal of molecular sciences* 19 (7) (2018) 2065.
- [8] M. Q. Nicol, B. M. Dutia, The role of macrophages in influenza A virus infection, *Future Virology* 9 (9) (2014) 847–862.
- [9] T. M. Tumpey, A. García-Sastre, J. K. Taubenberger, P. Palese, D. E. Swayne, M. J. Pantin-Jackwood, S. Schultz-Cherry, A. Solórzano, N. Van Rooijen, J. M. Katz, et al., Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice, *Journal of virology* 79 (23) (2005) 14933–14944.

- 439 [10] C. Purnama, S. L. Ng, P. Tetlak, Y. A. Setiagani, M. Kandasamy,
440 S. Baalasubramanian, K. Karjalainen, C. Ruedl, Transient ablation of
441 alveolar macrophages leads to massive pathology of influenza infection
442 without affecting cellular adaptive immunity, *European journal of im-*
443 *munology* 44 (7) (2014) 2003–2012.
- 444 [11] M. D. Tate, D. L. Pickett, N. van Rooijen, A. G. Brooks, P. C. Reading,
445 Critical role of airway macrophages in modulating disease severity dur-
446 ing influenza virus infection of mice, *Journal of virology* 84 (15) (2010)
447 7569–7580.
- 448 [12] H. M. Kim, Y.-W. Lee, K.-J. Lee, H. S. Kim, S. W. Cho, N. Van Rooi-
449 jen, Y. Guan, S. H. Seo, Alveolar macrophages are indispensable for
450 controlling influenza viruses in lungs of pigs, *Journal of virology* 82 (9)
451 (2008) 4265–4274.
- 452 [13] C. S. Zent, M. R. Elliott, Maxed out macs: physiologic cell clearance
453 as a function of macrophage phagocytic capacity, *The FEBS journal*
454 284 (7) (2017) 1021–1039.
- 455 [14] D. Dou, R. Revol, H. Östbye, H. Wang, R. Daniels, Influenza A virus
456 cell entry, replication, virion assembly and movement, *Frontiers in im-*
457 *munology* 9 (2018).
- 458 [15] J. B. Rubins, Alveolar macrophages: wielding the double-edged sword
459 of inflammation (2003).
- 460 [16] A. Iwasaki, P. S. Pillai, Innate immunity to influenza virus infection,
461 *Nature Reviews Immunology* 14 (5) (2014) 315–328.
- 462 [17] X. Chen, S. Liu, M. U. Goraya, M. Maarouf, S. Huang, J.-L. Chen, Host
463 immune response to influenza A virus infection, *Frontiers in immunology*
464 9 (2018) 320.
- 465 [18] P. J. Murray, T. A. Wynn, Protective and pathogenic functions of
466 macrophage subsets, *Nature reviews immunology* 11 (11) (2011) 723–
467 737.
- 468 [19] F. O. Martinez, A. Sica, A. Mantovani, M. Locati, et al., Macrophage
469 activation and polarization, *Front Biosci* 13 (1) (2008) 453–461.

- 470 [20] L. C. Davies, S. J. Jenkins, J. E. Allen, P. R. Taylor, Tissue-resident
471 macrophages, *Nature immunology* 14 (10) (2013) 986.
- 472 [21] T. Hussell, T. J. Bell, Alveolar macrophages: plasticity in a tissue-
473 specific context, *Nature reviews immunology* 14 (2) (2014) 81–93.
- 474 [22] A. J. Byrne, S. A. Mathie, L. G. Gregory, C. M. Lloyd, Pulmonary
475 macrophages: key players in the innate defence of the airways, *Thorax*
476 70 (12) (2015) 1189–1196.
- 477 [23] R. J. Snelgrove, J. Goulding, A. M. Didierlaurent, D. Lyonga, S. Vekaria,
478 L. Edwards, E. Gwyer, J. D. Sedgwick, A. N. Barclay, T. Hussell, A
479 critical function for CD200 in lung immune homeostasis and the severity
480 of influenza infection, *Nature immunology* 9 (9) (2008) 1074.
- 481 [24] C. Cheung, L. Poon, A. Lau, W. Luk, Y. Lau, K. Shortridge, S. Gordon,
482 Y. Guan, J. Peiris, Induction of proinflammatory cytokines in human
483 macrophages by influenza A (H5N1) viruses: a mechanism for the un-
484 usual severity of human disease?, *The Lancet* 360 (9348) (2002) 1831–
485 1837.
- 486 [25] J. Zhou, H. K. Law, C. Y. Cheung, I. H. Ng, J. M. Peiris, Y. L. Lau,
487 Differential expression of chemokines and their receptors in adult and
488 neonatal macrophages infected with human or avian influenza viruses,
489 *The Journal of infectious diseases* 194 (1) (2006) 61–70.
- 490 [26] J. Geiler, M. Michaelis, P. Sithisarn, J. Cinatl, Comparison of pro-
491 inflammatory cytokine expression and cellular signal transduction in
492 human macrophages infected with different influenza A viruses, *Med-
493 ical microbiology and immunology* 200 (1) (2011) 53–60.
- 494 [27] C. Wendy, R. W. Chan, J. Wang, E. A. Travanty, J. M. Nicholls,
495 J. M. Peiris, R. J. Mason, M. C. Chan, Viral replication and innate
496 host responses in primary human alveolar epithelial cells and alveolar
497 macrophages infected with influenza H5N1 and H1N1 viruses, *Journal
498 of virology* 85 (14) (2011) 6844–6855.
- 499 [28] S. M. Lee, J. L. Gardy, C. Cheung, T. K. Cheung, K. P. Hui, N. Y. Ip,
500 Y. Guan, R. E. Hancock, J. M. Peiris, Systems-level comparison of host-
501 responses elicited by avian H5N1 and seasonal H1N1 influenza viruses
502 in primary human macrophages, *PloS one* 4 (12) (2009) e8072.

- 503 [29] K. Högner, T. Wolff, S. Pleschka, S. Plog, A. D. Gruber, U. Kalinke,
504 H.-D. Walmrath, J. Bodner, S. Gattenlöhner, P. Lewe-Schlosser, et al.,
505 Macrophage-expressed IFN- β contributes to apoptotic alveolar epithelial
506 cell injury in severe influenza virus pneumonia, PLoS pathogens 9 (2)
507 (2013) e1003188.
- 508 [30] D. Kobasa, S. M. Jones, K. Shinya, J. C. Kash, J. Copps, H. Ebihara,
509 Y. Hatta, J. H. Kim, P. Halfmann, M. Hatta, et al., Aberrant innate
510 immune response in lethal infection of macaques with the 1918 influenza
511 virus, Nature 445 (7125) (2007) 319–323.
- 512 [31] M. Koutsakos, K. Kedzierska, K. Subbarao, Immune responses to avian
513 influenza viruses, The Journal of Immunology 202 (2) (2019) 382–391.
- 514 [32] L. A. Perrone, J. K. Plowden, A. García-Sastre, J. M. Katz, T. M.
515 Tumpey, H5N1 and 1918 pandemic influenza virus infection results in
516 early and excessive infiltration of macrophages and neutrophils in the
517 lungs of mice, PLoS pathogens 4 (8) (2008) e1000115.
- 518 [33] T. D. Cline, D. Beck, E. Bianchini, Influenza virus replication in
519 macrophages: balancing protection and pathogenesis, The Journal of
520 general virology 98 (10) (2017) 2401.
- 521 [34] A. M. Smith, J. A. McCullers, F. R. Adler, Mathematical model of a
522 three-stage innate immune response to a pneumococcal lung infection,
523 Journal of theoretical biology 276 (1) (2011) 106–116.
- 524 [35] A. M. Smith, F. R. Adler, R. M. Ribeiro, R. N. Gutenkunst, J. L.
525 McAuley, J. A. McCullers, A. S. Perelson, Kinetics of coinfection with
526 influenza A virus and Streptococcus pneumoniae, PLoS pathogens 9 (3)
527 (2013).
- 528 [36] J. E. Wigginton, D. Kirschner, A model to predict cell-mediated immune
529 regulatory mechanisms during human infection with mycobacterium tu-
530 berculosis, The Journal of Immunology 166 (3) (2001) 1951–1967.
- 531 [37] X. Li, M. K. Jolly, J. T. George, K. J. Pienta, H. Levine, Computational
532 modeling of the crosstalk between macrophage polarization and tumor
533 cell plasticity in the tumor microenvironment, Frontiers in oncology 9
534 (2019) 10.

- 535 [38] Y. Louzoun, C. Xue, G. B. Lesinski, A. Friedman, A mathematical
536 model for pancreatic cancer growth and treatments, *Journal of theoret-*
537 *ical biology* 351 (2014) 74–82.
- 538 [39] Y. Wang, T. Yang, Y. Ma, G. V. Halade, J. Zhang, M. L. Lindsey, Y.-F.
539 Jin, Mathematical modeling and stability analysis of macrophage acti-
540 vation in left ventricular remodeling post-myocardial infarction, *BMC*
541 *genomics* 13 (S6) (2012) S21.
- 542 [40] C. A. Beauchemin, A. Handel, A review of mathematical models of
543 influenza A infections within a host or cell culture: lessons learned and
544 challenges ahead, *BMC public health* 11 (S1) (2011) S7.
- 545 [41] A. M. Smith, A. S. Perelson, Influenza A virus infection kinetics: quan-
546 titative data and models, *Wiley Interdisciplinary Reviews: Systems Bi-*
547 *ology and Medicine* 3 (4) (2011) 429–445.
- 548 [42] A. Handel, L. E. Liao, C. A. Beauchemin, Progress and trends in math-
549 ematical modelling of influenza A virus infections, *Current Opinion in*
550 *Systems Biology* 12 (2018) 30–36.
- 551 [43] C. F. Nathan, H. W. Murray, M. E. Wiebe, B. Y. Rubin, Identification of
552 interferon- γ as the lymphokine that activates human macrophage oxida-
553 tive metabolism and antimicrobial activity., *The Journal of experimental*
554 *medicine* 158 (3) (1983) 670–689.
- 555 [44] S. Gordon, Alternative activation of macrophages, *Nature reviews im-*
556 *munology* 3 (1) (2003) 23.
- 557 [45] C. A. Janeway Jr, P. Travers, M. Walport, M. J. Shlomchik, The com-
558 plement system and innate immunity, in: *Immunobiology: The Immune*
559 *System in Health and Disease*. 5th edition, Garland Science, 2001.
- 560 [46] J.-M. Zhang, J. An, Cytokines, inflammation and pain, *International*
561 *anesthesiology clinics* 45 (2) (2007) 27.
- 562 [47] D. M. Mosser, J. P. Edwards, Exploring the full spectrum of macrophage
563 activation, *Nature reviews immunology* 8 (12) (2008) 958–969.
- 564 [48] M. Chan, C. Cheung, W. Chui, S. Tsao, J. Nicholls, Y. Chan, R. Chan,
565 H. Long, L. Poon, Y. Guan, et al., Proinflammatory cytokine responses

- 566 induced by influenza A (H5N1) viruses in primary human alveolar and
567 bronchial epithelial cells, *Respiratory research* 6 (1) (2005) 135.
- 568 [49] M. Adachi, S. Matsukura, H. Tokunaga, F. Kokubu, Expression of cy-
569 tokines on human bronchial epithelial cells induced by influenza virus
570 A, *International archives of allergy and immunology* 113 (1-3) (1997)
571 307–311.
- 572 [50] P. Baccam, C. Beauchemin, C. A. Macken, F. G. Hayden, A. S. Perelson,
573 Kinetics of influenza A virus infection in humans, *Journal of virology*
574 80 (15) (2006) 7590–7599.
- 575 [51] P. Cao, A. W. Yan, J. M. Heffernan, S. Petrie, R. G. Moss, L. A. Car-
576 olan, T. A. Guarnaccia, A. Kelso, I. G. Barr, J. McVernon, et al., Innate
577 immunity and the inter-exposure interval determine the dynamics of sec-
578 ondary influenza virus infection and explain observed viral hierarchies,
579 *PLoS computational biology* 11 (8) (2015) e1004334.
- 580 [52] R. Eftimie, H. Hamam, Modelling and investigation of the CD4+ T
581 cells–macrophages paradox in melanoma immunotherapies, *Journal of*
582 *theoretical biology* 420 (2017) 82–104.
- 583 [53] K. A. Pawelek, G. T. Huynh, M. Quinlivan, A. Cullinane, L. Rong, A. S.
584 Perelson, Modeling within-host dynamics of influenza virus infection
585 including immune responses, *PLoS computational biology* 8 (6) (2012)
586 e1002588.
- 587 [54] H. Miao, J. A. Hollenbaugh, M. S. Zand, J. Holden-Wiltse, T. R. Mos-
588 mann, A. S. Perelson, H. Wu, D. J. Topham, Quantifying the early im-
589 mune response and adaptive immune response kinetics in mice infected
590 with influenza A virus, *Journal of virology* 84 (13) (2010) 6687–6698.
- 591 [55] P. Cao, Z. Wang, A. W. Yan, J. McVernon, J. Xu, J. M. Heffernan,
592 K. Kedzierska, J. M. McCaw, On the role of CD8+ T cells in determining
593 recovery time from influenza virus infection, *Frontiers in immunology* 7
594 (2016) 611.
- 595 [56] M. J. Killip, E. Fodor, R. E. Randall, Influenza virus activation of the
596 interferon system, *Virus research* 209 (2015) 11–22.

- 597 [57] H. M. Dobrovolsky, M. J. Baron, R. Gieschke, B. E. Davies, N. L. Jumbe,
598 C. A. Beauchemin, Exploring cell tropism as a possible contributor to
599 influenza infection severity, *PloS one* 5 (11) (2010) e13811.
- 600 [58] L. Canini, F. Carrat, Population modeling of influenza A/H1N1 virus
601 kinetics and symptom dynamics, *Journal of virology* 85 (6) (2011) 2764–
602 2770.
- 603 [59] C. Hadjichrysanthou, E. Cauët, E. Lawrence, C. Vegvari, F. De Wolf,
604 R. M. Anderson, Understanding the within-host dynamics of influenza A
605 virus: from theory to clinical implications, *Journal of The Royal Society*
606 *Interface* 13 (119) (2016) 20160289.
- 607 [60] K.-Y. Yuen, P. Chan, M. Peiris, D. Tsang, T. Que, K. Shortridge,
608 P. Cheung, W. To, E. Ho, R. Sung, et al., Clinical features and rapid
609 viral diagnosis of human disease associated with avian influenza A H5N1
610 virus, *The Lancet* 351 (9101) (1998) 467–471.
- 611 [61] M. D. De Jong, C. P. Simmons, T. T. Thanh, V. M. Hien, G. J. Smith,
612 T. N. B. Chau, D. M. Hoang, N. V. V. Chau, T. H. Khanh, V. C. Dong,
613 et al., Fatal outcome of human influenza A (H5N1) is associated with
614 high viral load and hypercytokinemia, *Nature medicine* 12 (10) (2006)
615 1203–1207.
- 616 [62] C. R. Baskin, H. Bielefeldt-Ohmann, T. M. Tumpey, P. J. Sabourin,
617 J. P. Long, A. García-Sastre, A.-E. Tolnay, R. Albrecht, J. A. Pyles,
618 P. H. Olson, et al., Early and sustained innate immune response de-
619 fines pathology and death in nonhuman primates infected by highly
620 pathogenic influenza virus, *Proceedings of the National Academy of Sci-*
621 *ences* 106 (9) (2009) 3455–3460.
- 622 [63] P. J. Murray, Macrophage polarization, *Annual review of physiology* 79
623 (2017) 541–566.
- 624 [64] L. Kaiser, R. S. Fritz, S. E. Straus, L. Gubareva, F. G. Hayden, Symp-
625 tom pathogenesis during acute influenza: interleukin-6 and other cy-
626 tokine responses, *Journal of medical virology* 64 (3) (2001) 262–268.
- 627 [65] F. G. Hayden, R. Fritz, M. C. Lobo, W. Alvord, W. Strober, S. E.
628 Straus, Local and systemic cytokine responses during experimental hu-

- man influenza a virus infection. relation to symptom formation and host defense., *The Journal of clinical investigation* 101 (3) (1998) 643–649.
- [66] J. Lv, Y. Hua, D. Wang, A. Liu, J. An, A. Li, Y. Wang, X. Wang, N. Jia, Q. Jiang, Kinetics of pulmonary immune cells, antibody responses and their correlations with the viral clearance of influenza A fatal infection in mice, *Virology journal* 11 (1) (2014) 57.
- [67] F. Carrat, E. Vergu, N. M. Ferguson, M. Lemaitre, S. Cauchemez, S. Leach, A.-J. Valleron, Time lines of infection and disease in human influenza: a review of volunteer challenge studies, *American journal of epidemiology* 167 (7) (2008) 775–785.
- [68] J. R. Aldridge, C. E. Moseley, D. A. Boltz, N. J. Negovetich, C. Reynolds, J. Franks, S. A. Brown, P. C. Doherty, R. G. Webster, P. G. Thomas, TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection, *Proceedings of the National Academy of Sciences* 106 (13) (2009) 5306–5311.
- [69] K. L. Lin, Y. Suzuki, H. Nakano, E. Ramsburg, M. D. Gunn, CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality, *The Journal of Immunology* 180 (4) (2008) 2562–2572.
- [70] S. Davidson, S. Crotta, T. M. McCabe, A. Wack, Pathogenic potential of interferon α β in acute influenza infection, *Nature communications* 5 (1) (2014) 1–15.
- [71] P. Dhar, J. McAuley, The role of the cell surface mucin MUC1 as a barrier to infection and regulator of inflammation., *Frontiers in cellular and infection microbiology* 9 (2019) 117.
- [72] J. McAuley, L. Corcilius, H. Tan, R. Payne, M. McGuckin, L. Brown, The cell surface mucin MUC1 limits the severity of influenza A virus infection, *Mucosal immunology* 10 (6) (2017) 1581.
- [73] A. C. Tan, E. J. Mifsud, W. Zeng, K. Edenborough, J. McVernon, L. E. Brown, D. C. Jackson, Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice, *Molecular pharmaceutics* 9 (9) (2012) 2710–2718.

- 661 [74] B. Y. Chua, C. Y. Wong, E. J. Mifsud, K. M. Edenborough, T. Sekiya,
 662 A. C. Tan, F. Mercuri, S. Rockman, W. Chen, S. J. Turner, et al., Inac-
 663 tivated influenza vaccine that provides rapid, innate-immune-system-
 664 mediated protection and subsequent long-term adaptive immunity,
 665 MBio 6 (6) (2015) e01024–15.